Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074253 | 0.85 | MTNR1A (0.54) | MTNR1AMTNR1BKMT2ALMNAMEN1 | |
| SCHEMBL18607400 | 0.84 | MTNR1A (0.63) | MTNR1AMTNR1BKMT2ALMNAMEN1 | |
| SCHEMBL14241867 | 0.83 | TAAR1 (0.56) | MTNR1AMTNR1BTAAR1CNR1TRPV1 | |
| SCHEMBL17790724 | 0.83 | MTNR1A (0.63) | MTNR1AMTNR1BTAAR1CNR1TRPV1 | |
| SCHEMBL5988458 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BKMT2ALMNAMEN1 | |
| SCHEMBL8229644 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BKMT2ALMNAMEN1 | |
| SCHEMBL29941696 | 0.81 | RIPK1 (0.61) | LMNATSHR | |
| SCHEMBL1685923 | 0.81 | RIPK1 (0.61) | LMNATSHR | |
| SCHEMBL14045177 | 0.81 | NPC1 (0.58) | TAAR1CNR1TRPV1KMT2ALMNA | |
| SCHEMBL18198068 | 0.81 | MPO (0.54) | KMT2AMEN1TSHRMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268520-A1 | USE OF SUBSTITUTED PYRROLIDINONES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE OF PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021163467-A1 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-19 | — | — | WO | disclosed |
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| CN-101501036-B | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA | 2013-04-17 | — | — | CN | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| CN-1441775-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6545008-B1 | Inhibitory activity against gastric acid secretion | YUHAN CORPORATION (KR) | 2003-04-08 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1131312-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029403-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | MTNR1A 251/4885MTNR1B 219/4885TAAR1 259/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | MTNR1A 4023/4885MTNR1B 3828/4885TAAR1 2149/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | MTNR1A 4023/4885MTNR1B 3828/4885TAAR1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.